Influenza A virus vaccine H5N1 - Green Cross/Mogam Biotechnology Research Institute

Drug Profile

Influenza A virus vaccine H5N1 - Green Cross/Mogam Biotechnology Research Institute

Alternative Names: MG 1109

Latest Information Update: 15 Feb 2016

Price : $50

At a glance

  • Originator Green Cross
  • Class Influenza A virus H5N1 vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Influenza A virus H5N1 subtype

Most Recent Events

  • 15 Feb 2016 MG 1109 is still in development for Influenza-A virus H5N1 subtype (prevention) in South Korea
  • 01 Mar 2014 Green Cross Corporation completes a phase III trial in Influenza-A virus H5N1 subtype (prevention) in South Korea (NCT01987011)
  • 31 Jul 2013 Phase-III clinical trials in Influenza-A virus H5N1 subtype (prevention) in South Korea (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top